BioPharma Clinical Trials
Jadeite Medicines Transfers NDA for Odevixibat in PFIC to Ipsen for Commercialization in Japan
Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered in Tokyo, Japan (President & CEO, Eiichi Takahashi...
December 26, 2024 | News
Ractigen Therapeutics Doses First Patient in Phase I Trial of RAG-17 for SOD1-Linked ALS
Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosin...
December 25, 2024 | News
Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in NSCLC
Daiichi Sankyo and AstraZeneca have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DX...
December 25, 2024 | News
Keymed Biosciences Secures NMPA Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyposis
Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New D...
December 24, 2024 | News
Ellipses Pharma Launches Middle East’s First Large-Scale Oncology Phase 1/2 Clinical Study
Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an...
December 23, 2024 | News
YolTech Therapeutics Advances YOLT-201 Gene-Editing Therapy to Dose-Expansion Phase in ATTR Amyloidosis Clinical Trial
YolTech Therapeutics announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editin...
December 23, 2024 | News
Certa Therapeutics Strengthens Asia-Pacific Leadership with Acquisition of Melbourne-Based OccuRx to Advance GPR68-Driven Fibrotic Disease Therapies
Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces the acqu...
December 19, 2024 | News
Sanofi and Teva Report Positive Phase 2b Results for Duvakitug in Ulcerative Colitis and Crohn’s Disease
Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpo...
December 18, 2024 | News
Australia’s Cartherics Secures $300K G-Rex Grant to Advance Manufacturing of Allo CAR-iNK Cells for Ovarian Cancer Trials
- Cartherics has received a US$300K G-Rex grant to support its ‘in house’ manufacturing program- Funding will enable Cartherics to generate cru...
December 18, 2024 | News
Menarini Group Reports Positive Phase 3 Results for Obicetrapib in Reducing LDL-C Levels
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapie...
December 17, 2024 | News
Innovent Biologics and Lilly Collaborate to Bring Novel BTK Inhibitor Jaypirca® to Mainland China
Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ...
December 16, 2024 | News
HiRO Partners with South Korea’s CHA Bundang Medical Center to Advance Global Clinical Trials
Harvest Integrated Research Organization (HiRO), a boutique global clinical research organization (CRO) providing cross-border clinical trial sol...
December 16, 2024 | News
ADELA Phase III Trial Combines Elacestrant and Everolimus to Tackle Advanced ER+/HER2- Breast Cancer with ESR1 Mutations
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breas...
December 13, 2024 | News
CureGene Secures NMPA Approval for Clinical Trial of Novel Antiplatelet Drug CG-0255 in China
CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular...
December 13, 2024 | News
Most Read
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
